Bristol-Myers Squibb Is A High Yielding Blue-Chip That Should Appreciate
koto_feja/E+ via Getty Images
Bristol-Myers Squibb (BMY) should do well in the second half of 2021, and into 2022. The company has not been in news much lately, as it was not a candidate for a Covid-19 vaccine, but it remains a blue-chip Pharma with a strong…
